Enhancing evidence-based care using trial emulation in electronic health records: real-world effects of empagliflozin in people with type 2 diabetes
Patients prescribed empagliflozin in real-world settings differ substantially from those enrolled in the EMPA-REG RCT. Using electronic health records, we demonstrate that the mortality benefit observed in EMPA-REG extends to a broader, more diverse real-world population, including those excluded from the original RCT. These findings provide a novel source of real-world evidence supporting the wider use of empagliflozin in routine clinical practice.
Authors
- David Ryan (ORCID: https://orcid.org/0000-0002-1264-7165)
- Patrick Bidulka (ORCID: https://orcid.org/0000-0001-7644-2030)
- K. Diaz-Ordaz
- Ajay M. Shah (ORCID: https://orcid.org/0000-0002-6547-0631)
- Elizabeth Williamson
- R Thomas Lumbers
- Ruth H Keogh
Institutions
- London School of Hygiene & Tropical Medicine (GB)
- University College London (GB)
Publication Details
- Journal
- BMJ Open Diabetes Research & Care
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1136/bmjdrc-2025-005672
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wellcome Trust
- UK Research and Innovation
- National Institute for Health and Care Research
- British Heart Foundation
- Department of Health and Social Care
- University College London
- Medical Research Council